- $15.57bn
- $14.73bn
- $2.32bn
U.S. RESEARCH ROUNDUP-ADM, Pinterest, Ul Solutions
Brief: Exelixis Inc - Authorizes $750 Million Stock Repurchase By 2026 - SEC Filing
Exelixis Q3 revenue beats analyst expectations
Brief: Exelixis Q3 Revenue USD 597.8 Million Vs. IBES Estimate USD 590.2 Million
Brief: Exelixis announces detailed results from late-stage pivotal trial
Brief: Exelixis Says Cabometyx Reduced Risk Of Disease Progression Or Death By 81% Versus Placebo In Patients With Advanced Lung Or Thymic Neuroendocrine Tumors
Brief: Exelixis Announces Appointment Of Dana T. Aftab, Ph.D. As Executive Vice President, Research And Development
Exelixis Inc reports results for the quarter ended June 30 - Earnings Summary
Exelixis Q2 adjusted EPS beats expectations
Exelixis rises after cancer therapy succeeds in late-stage study
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment
U.S. STOCKS ON THE MOVE-AbbVie, Millrose Properties, European Wax Center
Exelixis hits 25-year high after lifting 2025 revenue forecast
Exelixis rises after lifting 2025 revenue forecast
U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth
Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
Exelixis Inc expected to post earnings of 36 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Domino's Pizza, Prologis, Springworks Therapeutics
U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax